Acelyrin Enters The Spotlight As NASDAQ Debut Dawns
The US biotech intends to use the proceeds from its upcoming IPO to advance lead candidate izokibep, an interleukin-17A inhibitor that is showing potential as a treatment for hidradenitis suppurativa.
You may also be interested in...
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”